{ "company": "Hologic", "ticker": "HOLX", "period": { "from": "2026-03-22", "to": "2026-04-21", "days": 30 }, "sentiment_breakdown": { "positive": 40, "negative": 30, "neutral": 55 }, "synthesis": { "executive_summary": "Sentiment analysis for Hologic (HOLX) from 2026-03-22 to 2026-04-21. Analyzed 125 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "Mammography Workstation Market to Grow by $500 Million During 2026-2030 Led by Siemens Healthineers, Fujifilm, and Koninklijke Philips", "date": "2026-04-01", "source": "news", "score": 1.0 }, { "title": "Supporting Women’s Health Can Unlock Workforce Potential. Here’s What Employers and Allies Can Do", "date": "2026-04-14", "source": "news", "score": 0.949 }, { "title": "Dengue Testing Market Size to be Valued at USD 971.11 Million by 2035; Industry Growth is Driven by the Increase in Dengue Cases in Tropical and Sub-tropical Nations Globally | SNS Insider", "date": "2026-04-20", "source": "news", "score": 0.863 }, { "title": "Hologic Stock 2026: Buy or Sell HOLX as Blackstone-TPG Buyout Nears Completion With $76 Cash Offer Plus CVR", "date": "2026-04-12", "source": "news", "score": 0.827 }, { "title": "Advent, Avista, Main Post bet on personal care; Underinvested women’s health draws in private equity", "date": "2026-04-10", "source": "news", "score": 0.751 }, { "title": "Wound Healing Devices Market Set for Sustained Growth at 5.07% CAGR Through 2032: DelveInsight | Smith & Nephew, ConvaTec, and Mölnlycke Health Care", "date": "2026-04-14", "source": "alpha_vantage", "score": 0.7 }, { "title": "Supporting Women’s Health Can Unlock Workforce Potential. Here’s What Employers and Allies Can Do", "date": "2026-04-14", "source": "news", "score": 0.681 }, { "title": "Positive nucleic acid amplification test results are rarely indicative of a viable rectal Chlamydia trachomatis infection among men with anal exposures other than receptive anal sex.", "date": "2026 Mar 2", "source": "pubmed", "score": 0.557 }, { "title": "Hologic Stock at 52-Week High in 2026: Buy or Sell Ahead of $18.3 Billion Blackstone Takeover Closure?", "date": "2026-04-07", "source": "news", "score": 0.542 }, { "title": "Peer- and nurse-led outreach, financial incentives, and point-of-care testing to enhance testing and treatment for hepatitis C among people who have used drugs or experienced homelessness: The REACH_U Study.", "date": "2026 Apr 7", "source": "pubmed", "score": 0.527 } ], "top_negative": [ { "title": "Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.", "date": "2026-04-21", "source": "pubmed", "score": -0.898 }, { "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider", "date": "2026-04-13", "source": "news", "score": -0.869 }, { "title": "Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology", "date": "2026-04-09", "source": "news", "score": -0.823 }, { "title": "Mammography Devices Market to Reach $3.81 Billion by 2030, Driven by Technological Advancements and Rising Breast Cancer Awareness", "date": "2026-03-27", "source": "news", "score": -0.727 }, { "title": "US stock market today: US stocks rise as Dow, S&P 500 and Nasdaq stay in green, while Nvidia and Tesla stocks continue to slip", "date": "2026-04-06", "source": "news", "score": -0.671 }, { "title": "Impact of less invasive axillary staging procedures after neoadjuvant systemic therapy on adjuvant systemic therapy indications in HER2-positive and triple-negative breast cancer.", "date": "2026 Apr 3", "source": "pubmed", "score": -0.66 }, { "title": "Informative High-Risk HPV Genotyping in Cervical Cancer Screening: Integrated Analysis of Cytology and p16/Ki67 Dual Staining.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.66 }, { "title": "Long-read sequencing identifies aberrant fragmentation patterns linked to elevated cell-free DNA levels in cancer.", "date": "2026 Apr 1", "source": "pubmed", "score": -0.66 }, { "title": "Recent Trends in Whole-Breast Irradiation Versus Partial-Breast Irradiation in Ductal Carcinoma in situ with Breast-Conserving Surgery 2011-2021: A National Cancer Database Study.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.66 }, { "title": "Late distant recurrence prediction model in premenopausal women with ER-positive/HER 2-negative breast cancer: A multicenter retrospective study.", "date": "2026-04-21", "source": "pubmed", "score": -0.66 } ], "raw_data": { "total_items": 125, "items": [ { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-04-07", "url": "https://www.sec.gov/Archives/edgar/data/859737/000119312526144632/0001193125-26-144632-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-04-06", "url": "https://www.sec.gov/Archives/edgar/data/859737/000114036126013235/0001140361-26-013235-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Dengue Testing Market Size to be Valued at USD 971.11 Million by 2035; Industry Growth is Driven by the Increase in Dengue Cases in Tropical and Sub-tropical Nations Globally | SNS Insider", "description": "Dengue testing market grows with rising cases, rapid diagnostics, RT-PCR adoption, and strong public health initiatives driving global demand....", "url": "https://www.globenewswire.com/news-release/2026/04/20/3276781/0/en/Dengue-Testing-Market-Size-to-be-Valued-at-USD-971-11-Million-by-2035-Industry-Growth-is-Driven-by-the-Increase-in-Dengue-Cases-in-Tropical-and-Sub-tropical-Nations-Globally-SNS-In.html", "date": "2026-04-20", "published_at": "2026-04-20T09:30:00Z", "sentiment": { "label": "positive", "score": 0.863, "confidence": 0.86 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Radiology AI Global Market Research and Forecast Report 2026-2030: Opportunities in Growing Demand for Platform, Multi-Modal Data, and OEM Integration (Pacs/Ehr/Marketplaces)", "description": "The radiology AI market is set to explode from USD 0.76 billion in 2025 to USD 2.27 billion by 2030, growing at a 24.5% CAGR. The surge is driven by the adoption of AI tools for cancer detection, lesion segmentation, and workflow optimization, particularly wi…", "url": "https://www.globenewswire.com/news-release/2026/04/17/3276394/28124/en/Radiology-AI-Global-Market-Research-and-Forecast-Report-2026-2030-Opportunities-in-Growing-Demand-for-Platform-Multi-Modal-Data-and-OEM-Integration-Pacs-Ehr-Marketplaces.html", "date": "2026-04-17", "published_at": "2026-04-17T16:20:00Z", "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "RNA Extraction and RNA Purification Research Report 2025: Market Industry Trends and Global Forecasts to 2035 - Approximately 175 Extraction Instruments Have Been Developed Across 70 Players", "description": "Key market opportunities in the RNA extraction and purification sector include the growing demand for RNA-based therapies and diagnostics, the development of user-friendly and automated kits, and the expanding academic and research activities. North America r…", "url": "https://www.globenewswire.com/news-release/2026/04/17/3275985/28124/en/RNA-Extraction-and-RNA-Purification-Research-Report-2025-Market-Industry-Trends-and-Global-Forecasts-to-2035-Approximately-175-Extraction-Instruments-Have-Been-Developed-Across-70-.html", "date": "2026-04-17", "published_at": "2026-04-17T09:03:00Z", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "TD Cowen Cuts TPG PT Amid Q1 Preview for Asset Managers", "description": "TPG Inc. (NASDAQ:TPG) is included among the 14 Value Stocks with Highest Dividends. On April 9, TD Cowen analyst Bill Katz lowered the firm’s price...", "url": "https://finance.yahoo.com/markets/stocks/articles/td-cowen-cuts-tpg-pt-052156797.html", "date": "2026-04-15", "published_at": "2026-04-15T05:21:56Z", "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Financial Post", "title": "Supporting Women’s Health Can Unlock Workforce Potential. Here’s What Employers and Allies Can Do", "description": "Vital Talks panel discussion will explore how better support for women’s health can drive workforce participation, financial security, and economic growth TORONTO, April 14, 2026 (GLOBE NEWSWIRE) — Women’s Health Collective Canada is pleased to announce the n…", "url": "https://financialpost.com/globe-newswire/supporting-womens-health-can-unlock-workforce-potential-heres-what-employers-and-allies-can-do", "date": "2026-04-14", "published_at": "2026-04-14T18:26:06Z", "sentiment": { "label": "positive", "score": 0.949, "confidence": 0.95 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Supporting Women’s Health Can Unlock Workforce Potential. Here’s What Employers and Allies Can Do", "description": "Investing in women’s health can boost workforce participation and unlock billions for Canada’s economy—this panel explores what employers can do now....", "url": "https://www.globenewswire.com/news-release/2026/04/14/3273826/0/en/Supporting-Women-s-Health-Can-Unlock-Workforce-Potential-Here-s-What-Employers-and-Allies-Can-Do.html", "date": "2026-04-14", "published_at": "2026-04-14T18:24:00Z", "sentiment": { "label": "positive", "score": 0.681, "confidence": 0.68 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider", "description": "Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies. Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies.", "url": "https://www.globenewswire.com/news-release/2026/04/13/3272705/0/en/Companion-Diagnostics-Market-Size-is-Projected-to-Hit-USD-26-38-Billion-by-2035-SNS-Insider.html", "date": "2026-04-13", "published_at": "2026-04-13T15:30:00Z", "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "news", "source_name": "Ibtimes.com.au", "title": "Hologic Stock 2026: Buy or Sell HOLX as Blackstone-TPG Buyout Nears Completion With $76 Cash Offer Plus CVR", "description": "NEW YORK — Hologic Inc. (NASDAQ: HOLX) shares traded near $76 as of April 10, 2026, trading close to the $76-per-share cash offer from private equity firms Blackstone and TPG in a deal valued at up to $79 per share including a contingent value right, as the m…", "url": "https://www.ibtimes.com.au/hologic-stock-2026-buy-sell-holx-blackstone-tpg-buyout-nears-completion-76-cash-offer-plus-cvr-1866229", "date": "2026-04-12", "published_at": "2026-04-12T09:51:58Z", "sentiment": { "label": "positive", "score": 0.827, "confidence": 0.83 } }, { "source": "news", "source_name": "Pehub.com", "title": "Advent, Avista, Main Post bet on personal care; Underinvested women’s health draws in private equity", "description": "Blackstone and TPG announced the closing of their take-private of Hologic, a women’s medtech developer based in Marlborough, Massachusetts, earlier this week.\nThe post Advent, Avista, Main Post bet on personal care; Underinvested women’s health draws in priva…", "url": "https://www.pehub.com/advent-avista-main-post-bet-on-personal-care-underinvested-womens-health-draws-in-private-equity/", "date": "2026-04-10", "published_at": "2026-04-10T13:39:39Z", "sentiment": { "label": "positive", "score": 0.751, "confidence": 0.75 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology", "description": "Market growth is driven by rising cancer prevalence, demand for minimally invasive procedures, and advances in precision diagnostics....", "url": "https://www.globenewswire.com/news-release/2026/04/09/3271135/0/en/Global-Noninvasive-Cancer-Diagnostics-Market-to-Reach-165-2-Billion-by-2030-as-Liquid-Biopsy-AI-Enabled-Screening-and-Multi-Cancer-Detection-Tests-Transform-Oncology.html", "date": "2026-04-09", "published_at": "2026-04-09T14:12:00Z", "sentiment": { "label": "negative", "score": -0.823, "confidence": 0.82 } }, { "source": "news", "source_name": "Ibtimes.com.au", "title": "Hologic Stock at 52-Week High in 2026: Buy or Sell Ahead of $18.3 Billion Blackstone Takeover Closure?", "description": "Hologic Inc. shares hit a fresh 52-week high of $76.07 Tuesday as the medical technology company's $18.3 billion buyout by private equity giants Blackstone and TPG appeared on track to close as early as April 7, leaving investors with a narrow window to decid…", "url": "https://www.ibtimes.com.au/hologic-stock-52-week-high-2026-buy-sell-ahead-183-billion-blackstone-takeover-closure-1865697", "date": "2026-04-07", "published_at": "2026-04-07T14:45:36Z", "sentiment": { "label": "positive", "score": 0.542, "confidence": 0.54 } }, { "source": "news", "source_name": "The Times of India", "title": "US stock market today: US stocks rise as Dow, S&P 500 and Nasdaq stay in green, while Nvidia and Tesla stocks continue to slip", "description": "US stock market today is moving higher. The Dow is up over 99 points. The S&P 500 has crossed 6,600. The Nasdaq is close to 22,000. Markets are clearly in the green. But not everything is strong. Nvidia and Tesla are still under pressure. That’s catching atte…", "url": "https://economictimes.indiatimes.com/news/international/us/us-stock-market-today-us-stocks-rise-as-dow-sp-500-and-nasdaq-stay-in-green-while-nvidia-and-tesla-stocks-continue-to-slip/articleshow/130064313.cms", "date": "2026-04-06", "published_at": "2026-04-06T15:11:09Z", "sentiment": { "label": "negative", "score": -0.671, "confidence": 0.67 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Hologic CEO Steve MacMillan to retire after go-private deal", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_1646aab4-2597-4d82-a27e-f62d118b8039", "date": "2026-04-06", "published_at": "2026-04-06T10:49:44Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider", "description": "Molecular diagnostics market to grow from $18.26 Bn to $43.50 Bn by 2035, driven by PCR, NGS, and demand for early, precise diagnosis....", "url": "https://www.globenewswire.com/news-release/2026/04/03/3267957/0/en/Molecular-Diagnostics-Market-Size-is-Expected-to-Reach-USD-43-50-Billion-by-2035-Owing-to-the-Surging-Demand-for-Accurate-and-Early-Disease-Detection-Globally-SNS-Insider.html", "date": "2026-04-03", "published_at": "2026-04-03T09:00:00Z", "sentiment": { "label": "negative", "score": -0.226, "confidence": 0.23 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Mammography Workstation Market to Grow by $500 Million During 2026-2030 Led by Siemens Healthineers, Fujifilm, and Koninklijke Philips", "description": "The market is set for strong growth with the integration of advanced imaging technologies and software-centric solutions The market is set for strong growth with the integration of advanced imaging technologies and software-centric solutions", "url": "https://www.globenewswire.com/news-release/2026/04/01/3266486/28124/en/Mammography-Workstation-Market-to-Grow-by-500-Million-During-2026-2030-Led-by-Siemens-Healthineers-Fujifilm-and-Koninklijke-Philips.html", "date": "2026-04-01", "published_at": "2026-04-01T11:01:00Z", "sentiment": { "label": "positive", "score": 1.0, "confidence": 1.0 } }, { "source": "news", "source_name": "Plos.org", "title": "Genotypic distribution and molecular epidemiology of HPV in women in the UAE using PNA-based RT PCR", "description": "Objectives This study aimed to determine the genotypic distribution and molecular epidemiology of HPVs in PAP smear samples of women in the UAE using a peptide nucleic acid (PNA)-based fluorescence melting curve analysis method. Methods A cross-sectional re…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346052", "date": "2026-03-31", "published_at": "2026-03-31T14:00:00Z", "sentiment": { "label": "negative", "score": -0.361, "confidence": 0.36 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook", "description": "Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and liquid biopsy tech Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and li…", "url": "https://www.globenewswire.com/news-release/2026/03/30/3264368/28124/en/Oncology-Biomarkers-Market-Trends-and-Investment-Opportunities-Report-2026-2030-Global-Regional-and-Country-Level-Outlook.html", "date": "2026-03-30", "published_at": "2026-03-30T08:58:00Z", "sentiment": { "label": "positive", "score": 0.153, "confidence": 0.15 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oncology Devices: Markets and Companies Analysis Report 2026 - Eckert & Ziegler BEBIG, Oncura, GE Healthcare Lead the $210 Billion Industry; Expected to Reach $397 Billion by 2030", "description": "Expansion in personalized treatments, outpatient facilities, AI diagnostics, precision therapies, and innovations in chemotherapy & diagnostics fuel the market Expansion in personalized treatments, outpatient facilities, AI diagnostics, precision therapies, a…", "url": "https://www.globenewswire.com/news-release/2026/03/30/3264356/28124/en/Oncology-Devices-Markets-and-Companies-Analysis-Report-2026-Eckert-Ziegler-BEBIG-Oncura-GE-Healthcare-Lead-the-210-Billion-Industry-Expected-to-Reach-397-Billion-by-2030.html", "date": "2026-03-30", "published_at": "2026-03-30T08:31:00Z", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "news", "source_name": "Financial Post", "title": "Inside ‘Project Eagle,’ JPMorgan’s High-Wire Act to Fund EA Deal", "description": "The post from @realDonaldTrump landed at precisely 7:23 a.m. Inside JPMorgan Chase & Co., the final piece of Project Eagle was a go.", "url": "https://financialpost.com/pmn/business-pmn/inside-project-eagle-jpmorgans-high-wire-act-to-fund-ea-deal", "date": "2026-03-28", "published_at": "2026-03-28T19:38:06Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Mammography Devices Market to Reach $3.81 Billion by 2030, Driven by Technological Advancements and Rising Breast Cancer Awareness", "description": "Key market opportunities include advancements in digital and 3D mammography, integration of AI and CAD systems, expansion of portable units, and increased government support for early breast cancer detection. Growth in Asia-Pacific and rising breast cancer pr…", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263847/28124/en/Mammography-Devices-Market-to-Reach-3-81-Billion-by-2030-Driven-by-Technological-Advancements-and-Rising-Breast-Cancer-Awareness.html", "date": "2026-03-27", "published_at": "2026-03-27T14:30:00Z", "sentiment": { "label": "negative", "score": -0.727, "confidence": 0.73 } }, { "source": "news", "source_name": "Pehub.com", "title": "Women’s health ripe for private equity investments, finds Kearney’s Paula Bellostas Muguerza", "description": "Blackstone and TPG's $18.3bn take-private of Hologic, which is expected to close soon, is a bellwether.\nThe post Women’s health ripe for private equity investments, finds Kearney’s Paula Bellostas Muguerza appeared first on PE Hub.", "url": "https://www.pehub.com/?p=20000003725583", "date": "2026-03-26", "published_at": "2026-03-26T16:00:53Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "dicom-hl7-mcp added to PyPI", "description": "DICOM/HL7 Developer AI Assistant — MCP server for healthcare integration engineers", "url": "https://pypi.org/project/dicom-hl7-mcp/", "date": "2026-03-25", "published_at": "2026-03-25T17:27:47Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "New York Post", "title": "Iga Swiatek parts ways with tennis coach after stunning loss: ‘Worst nightmare’", "description": "Polish tennis star Iga Swiatek has parted ways with her coach, Wim Fissette, who joined in her 2024, after a \"nightmare\" second-round loss at the 2026 Miami Open.", "url": "https://nypost.com/2026/03/23/sports/iga-swiatek-parts-ways-with-tennis-coach-after-stunning-loss-worst-nightmare/", "date": "2026-03-23", "published_at": "2026-03-23T20:55:06Z", "sentiment": { "label": "negative", "score": -0.45, "confidence": 0.45 } }, { "source": "alpha_vantage", "title": "New Evidence Backs Hologic’s AI-Powered Mammography Technology for Detecting Challenging Cancers", "url": "https://www.biospace.com/press-releases/new-evidence-backs-hologics-ai-powered-mammography-technology-for-detecting-challenging-cancers", "date": "2026-04-20", "summary": "New research presented at the Society of Breast Imaging Symposium highlights Hologic’s AI-driven breast cancer detection technologies, particularly its effectiveness in identifying invasive lobular cancers, which are often challenging to detect. A study from Massachusetts General Hospital showed Hologic’s Genius AI® Detection solution accurately identified close to 90% of confirmed invasive lobular cancers, including 43% of those initially deemed negative by human radiologists. This underscores ", "sentiment_score": 0.780719, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "New Evidence Backs Hologic’s AI-Powered Mammography Technology for Detecting Challenging Cancers", "url": "https://www.01net.it/new-evidence-backs-hologics-ai-powered-mammography-technology-for-detecting-challenging-cancers/", "date": "2026-04-20", "summary": "New research presented at the Society of Breast Imaging (SBI) Symposium highlights the effectiveness of Hologic's AI-driven breast cancer detection technologies, particularly for challenging cases like invasive lobular cancer. A study by Massachusetts General Hospital retrospectively analyzed invasive lobular cancer cases, revealing that Hologic's Genius AI Detection solution identified and correctly localized nearly 90% of confirmed cases, including a significant percentage previously missed du", "sentiment_score": 0.419098, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "New Evidence Backs Hologic’s AI-Powered Mammography Technology for Detecting Challenging Cancers", "url": "https://www.morningstar.com/news/business-wire/20260420522939/new-evidence-backs-hologics-ai-powered-mammography-technology-for-detecting-challenging-cancers", "date": "2026-04-20", "summary": "New research presented at the Society of Breast Imaging Symposium highlights the effectiveness of Hologic’s AI-powered mammography technology, particularly its Genius AI Detection solution, in identifying invasive lobular cancers. This type of breast cancer is often challenging to detect using traditional mammography due to its unique growth pattern. The study, conducted by Massachusetts General Hospital, found that the AI technology correctly localized nearly 90% of confirmed invasive lobular c", "sentiment_score": 0.438044, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "New Evidence Backs Hologic’s AI-Powered Mammography Technology for Detecting Challenging Cancers", "url": "https://www.businesswire.com/news/home/20260420522939/en/New-Evidence-Backs-Hologics-AI-Powered-Mammography-Technology-for-Detecting-Challenging-Cancers", "date": "2026-04-20", "summary": "New research presented at the Society of Breast Imaging Symposium highlights Hologic’s AI-driven breast cancer detection technologies, particularly demonstrating high sensitivity in detecting invasive lobular cancers. This type of cancer is often challenging to identify on mammograms due to its unique growth patterns. The study underscores the potential of AI as a powerful supportive tool for radiologists, with the technology retrospectively identifying nearly 90% of confirmed invasive lobular c", "sentiment_score": 0.433838, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "New Evidence Backs Hologic’s AI-Powered Mammography Technology for Detecting Challenging Cancers", "url": "https://www.bastillepost.com/global/article/5790953-new-evidence-backs-hologics-ai-powered-mammography-technology-for-detecting-challenging-cancers", "date": "2026-04-20", "summary": "New research presented at the Society of Breast Imaging Symposium highlights the effectiveness of Hologic's AI-driven breast cancer detection technologies, particularly for challenging cases like invasive lobular cancer. A study demonstrated Hologic's Genius AI Detection solution identified nearly 90% of confirmed invasive lobular cancers, including 43% initially missed by radiologists. This evidence reinforces AI's role as a supportive tool for radiologists in detecting a broad spectrum of brea", "sentiment_score": 0.407806, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Hologic, Inc. (HOLX) Stock Analysis: Evaluating the Growth Potential in the Medical Instruments Sector", "url": "https://www.directorstalkinterviews.com/hologic-inc-holx-stock-analysis-evaluating-the-growth-potential-in-the-medical-instruments-sector/4121249485", "date": "2026-04-20", "summary": "Hologic, Inc. (HOLX), a key player in women's health medical instruments, shows consistent performance with a $16.97 billion market cap and a stock price at its 52-week peak of $76.01. The company's diverse product offerings, strong financial health with $848.6 million in free cash flow, and focus on reinvestment position it well for future growth despite no dividend yield. Analysts offer a cautious \"hold\" sentiment with a modest average target price, reflecting stability in a dynamic sector.", "sentiment_score": 0.429192, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Qiagen N.V. stock (NL0012169213): Why does its molecular diagnostics edge matter more for U.S. investors now?", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-why-does-its-molecular-diagnostics-edge/69193729", "date": "2026-04-18", "summary": "Qiagen N.V. is positioned as a leader in molecular diagnostics and life sciences tools, offering investors exposure to the growing genomics and precision medicine sectors. The company's \"sample-to-insight\" business model, robust product portfolio, and strong intellectual property provide a defensive yet growth-oriented profile, appealing to U.S. and English-speaking market investors seeking biotech exposure without the typical drug development risks. Analysts generally view Qiagen positively, ci", "sentiment_score": 0.228066, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.644024, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "[15-12G] HOLOGIC INC SEC Filing", "url": "https://www.stocktitan.net/sec-filings/HOLX/15-12g-hologic-inc-sec-filing-2bced7d42e25.html", "date": "2026-04-17", "summary": "Hologic, Inc. (HOLX) has filed Form 15-12G with the SEC, certifying the termination of its registration under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of its duty to file reports. This action follows the merger of Merger Sub Inc. with and into Hologic, Inc. on April 7, 2026, making Hologic a wholly-owned subsidiary of Hopper Parent Inc. The filing indicates there is now only one holder of record.", "sentiment_score": 0.032004, "sentiment_label": "Neutral", "relevance_score": 0.34553, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Is trending stock Hologic, Inc. (HOLX) a buy now?", "url": "https://www.msn.com/en-us/money/topstocks/is-trending-stock-hologic-inc-holx-a-buy-now/ar-AA1WYHoq?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-04-17", "summary": "The article poses a question about whether Hologic, Inc. (HOLX), a currently trending stock, is a good buying opportunity. The body of the article appears to be missing, as only \"MSN\" is provided as content, preventing a full analysis.", "sentiment_score": 0.048679, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Lobbying Update: $390,000 of HOLOGIC INC. lobbying was just disclosed", "url": "https://www.quiverquant.com/news/Lobbying+Update%3A+%24390%2C000+of+HOLOGIC+INC.+lobbying+was+just+disclosed", "date": "2026-04-16", "summary": "Hologic Inc. (HOLX) disclosed $390,000 in lobbying expenditures for Q1 2026, focusing on women's health issues, medical device tariffs, and the RESULTS Act. The article also details recent insider trading activity, with one sale totaling over $540,000, and institutional investor movements, showing both significant additions and removals of HOLX shares. Analyst price targets for HOLX are largely clustered around $78.0.", "sentiment_score": 0.014643, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "HOLX SEC Filings - Hologic Inc 10-K, 10-Q, 8-K Forms", "url": "https://www.stocktitan.net/sec-filings/HOLX/page-7.html", "date": "2026-04-16", "summary": "This page on Stock Titan provides comprehensive access to Hologic Inc. (HOLX) SEC filings, including annual 10-K reports, quarterly 10-Q statements, 8-K material event disclosures, and insider trading forms. It highlights recent filings related to executive stock units and a proposed merger with affiliates of Blackstone and TPG, offering AI-powered summaries for easier understanding. The platform tracks 78 SEC filings for HOLX, with the most recent being on November 6, 2025.", "sentiment_score": 0.126579, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "HOLX SEC Filings - Hologic Inc 10-K, 10-Q, 8-K Forms", "url": "https://www.stocktitan.net/sec-filings/HOLX/page-8.html", "date": "2026-04-16", "summary": "This page on Stock Titan provides comprehensive access to Hologic Inc. (HOLX) SEC filings, including annual 10-K reports, quarterly 10-Q reports, and 8-K material event disclosures. It details Hologic's operations in diagnostics, breast health, GYN surgical, and skeletal health, offering insights into financial performance and corporate events, such as a proposed merger with Blackstone and TPG affiliates. The platform enhances accessibility with AI-powered summaries and sentiment analysis for ke", "sentiment_score": 0.069044, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Dexcom (NASDAQ: DXCM) posts growth, seeks votes on board, pay and auditor", "url": "https://www.stocktitan.net/sec-filings/DXCM/def-14a-dexcom-inc-definitive-proxy-statement-57bd382a1f0b.html", "date": "2026-04-15", "summary": "DexCom, Inc. is seeking stockholder votes on the election of twelve directors, the ratification of Deloitte & Touche LLP as its 2026 auditor, and advisory approval of 2025 executive compensation. The company reported strong 2025 financial results, including $4.66 billion in revenue (up 16% from 2024) and $836.3 million in net income (up 45%), alongside strategic achievements like new product launches and expanded global access. The proxy statement also details a refreshed board structure, an emp", "sentiment_score": 0.113534, "sentiment_label": "Neutral", "relevance_score": 0.633502, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "AIP to acquire Avanos Medical in $1.27B go-private deal", "url": "https://www.medtechdive.com/news/aip-to-acquire-avanos-medical-in-127b-go-private-deal/817520/", "date": "2026-04-15", "summary": "American Industrial Partners (AIP) is set to acquire Avanos Medical in a $1.27 billion go-private deal, offering a 72.1% premium to its Monday closing stock price. Avanos, which generated $701.2 million in net sales last year, competes in specialty nutrition and pain management markets against major players. The acquisition is expected to provide Avanos with enhanced flexibility and resources to strengthen its competitive position and advance its innovation roadmap, aiming for $1 billion in reve", "sentiment_score": 0.14329, "sentiment_label": "Neutral", "relevance_score": 0.637359, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Baird Adjusts Medtronic Price Target to $93 From $92, Maintains Neutral Rating", "url": "https://www.marketscreener.com/news/baird-adjusts-medtronic-price-target-to-93-from-92-maintains-neutral-rating-ce7e50dcdc80f220", "date": "2026-04-15", "summary": "Baird has adjusted its price target for Medtronic (MDT) to $93, an increase from its previous target of $92, while maintaining a Neutral rating on the stock. This update reflects an analyst's revised outlook on the medical equipment manufacturer's valuation. The news comes amid several other analyst adjustments for Medtronic.", "sentiment_score": 0.103501, "sentiment_label": "Neutral", "relevance_score": 0.638208, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "AIP to acquire Avanos Medical in $1.27B go-private deal", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aip-acquire-avanos-medical-1-034405307.html", "date": "2026-04-14", "summary": "American Industrial Partners (AIP) has agreed to acquire Avanos Medical in a $1.27 billion go-private deal. The acquisition, which offers a 72.1% premium to Avanos's recent closing stock price, aims to strengthen Avanos's competitive position in the specialty nutrition and pain management markets. Avanos CEO Dave Pacitti stated that AIP's backing will support the company's innovation roadmap and goal of reaching $1 billion in revenue by 2030, following recent portfolio adjustments and restructur", "sentiment_score": -0.122687, "sentiment_label": "Neutral", "relevance_score": 0.56484, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Wound Healing Devices Market Set for Sustained Growth at 5.07% CAGR Through 2032: DelveInsight | Smith & Nephew, ConvaTec, and Mölnlycke Health Care", "url": "https://www.barchart.com/story/news/1303029/wound-healing-devices-market-set-for-sustained-growth-at-507-cagr-through-2032-delveinsight-smith-nephew-convatec-and-mlnlycke-health-care", "date": "2026-04-14", "summary": "The global wound healing devices market is projected to reach USD 42,320.35 million by 2032, growing at a CAGR of 5.07% from 2025. This growth is primarily driven by the increasing prevalence of chronic wounds, rising surgical procedures, and the adoption of technologically advanced wound care solutions. North America is expected to lead the market, while significant technological trends include AI-driven monitoring and smart dressings.", "sentiment_score": 0.127724, "sentiment_label": "Neutral", "relevance_score": 0.600605, "sentiment": { "label": "positive", "score": 0.7, "confidence": 0.7 } }, { "source": "alpha_vantage", "title": "Blackstone’s Cross Sector Deals Reshape Growth Story And Valuation Outlook", "url": "https://simplywall.st/stocks/us/diversified-financials/nyse-bx/blackstone/news/blackstones-cross-sector-deals-reshape-growth-story-and-valu", "date": "2026-04-14", "summary": "Blackstone (NYSE:BX) is actively expanding its reach through several cross-sector deals, including a potential bid for Stroer's European advertising business and an $18.3 billion acquisition of Hologic, further building its profile in digital assets and healthcare. These strategic moves, coupled with an Outperform rating from Oppenheimer, indicate a diversified growth strategy that is drawing significant market attention. Investors should monitor how these transactions impact Blackstone's earnin", "sentiment_score": 0.327116, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.735645, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "[EFFECT] HOLOGIC INC SEC Filing", "url": "https://www.stocktitan.net/sec-filings/HOLX/effect-hologic-inc-sec-filing-293b5136d509.html", "date": "2026-04-13", "summary": "This article reports on an EFFECT SEC filing by Hologic Inc. (HOLX) on April 13, 2026. The filing indicates a \"Neutral\" impact and sentiment. The article also provides an overview of recent news and other SEC filings related to Hologic Inc.", "sentiment_score": -0.086911, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "[EFFECT] HOLOGIC INC SEC Filing", "url": "https://www.stocktitan.net/sec-filings/HOLX/effect-hologic-inc-sec-filing-561211279fec.html", "date": "2026-04-13", "summary": "This article reports on an SEC filing (Form EFFECT) by Hologic Inc. (HOLX) indicating its effectiveness as of April 10, 2026. The filing has a neutral impact and sentiment. The article also provides a brief overview of Hologic Inc., including its market cap, industry, and recent news and SEC filings.", "sentiment_score": 0.048259, "sentiment_label": "Neutral", "relevance_score": 0.309668, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic Stock 2026: Buy or Sell HOLX as Blackstone-TPG Buyout Nears Completion With $76 Cash Offer Plus CVR", "url": "https://www.ibtimes.com.au/hologic-stock-2026-buy-sell-holx-blackstone-tpg-buyout-nears-completion-76-cash-offer-plus-cvr-1866229", "date": "2026-04-12", "summary": "Hologic Inc. (NASDAQ: HOLX) shares are trading near $76 as a buyout by Blackstone and TPG for $76 cash per share plus a contingent value right (CVR) nears completion in the first half of 2026. The deal, valued at up to $79 per share including the CVR, has led analysts to maintain a \"Hold\" rating on the stock, overshadowing traditional valuation metrics. The buyout offers a significant premium to pre-announcement trading levels and provides a clear exit path for public shareholders.", "sentiment_score": 0.141081, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Intuitive Surgical (ISRG) Gets a Buy from BTIG", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ISRG-Q/pressreleases/1261260/intuitive-surgical-isrg-gets-a-buy-from-btig/", "date": "2026-04-12", "summary": "BTIG analyst Ryan Zimmerman has reiterated a Buy rating on Intuitive Surgical (ISRG), setting a price target of $616.00. This follows a similar Buy rating from Goldman Sachs, despite Evercore ISI maintaining a Hold rating. The company recently reported strong quarterly results with a revenue of $2.87 billion and a net profit of $794.8 million for the quarter ending December 31.", "sentiment_score": 0.138083, "sentiment_label": "Neutral", "relevance_score": 0.634641, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic: $18.3 Billion Take-Private Deal Completed As Women’s Health MedTech Company Goes Private", "url": "https://pulse2.com/hologic-18-3-billion-take-private-deal-completed-as-womens-health-medtech-company-goes-private/", "date": "2026-04-11", "summary": "Hologic, a global women’s health medical technology company, has completed its $18.3 billion acquisition by funds managed by Blackstone and TPG, transitioning the company to private ownership. The deal, valued at up to $79 per share, includes a contingent value right and names José E. Almeida as the new CEO. Blackstone and TPG, along with minority investors, plan to support Hologic's mission to accelerate innovation and expand women's health initiatives globally.", "sentiment_score": 0.46478, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Bruker (NASDAQ: BRKR) sets 2026 virtual meeting, pay and auditor votes", "url": "https://www.stocktitan.net/sec-filings/BRKR/def-14a-bruker-corp-definitive-proxy-statement-3549714b6d3b.html", "date": "2026-04-10", "summary": "Bruker Corporation announced details for its 2026 Annual Meeting of Stockholders, which will be held virtually on May 21, 2026. Stockholders will vote on the election of three Class II directors, seek advisory approval for 2025 executive compensation, and ratify PricewaterhouseCoopers as the independent auditor for 2026. The proxy statement also highlights the company's pay-for-performance executive compensation philosophy tied to financial and individual objectives, despite a decline in organic", "sentiment_score": 0.243221, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.745876, "sentiment": { "label": "negative", "score": -0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Blackstone and TPG Complete Acquisition of Hologic; Names New CEO", "url": "https://medtechintelligence.com/news_article/blackstone-and-tpg-complete-acquisition-of-hologic-names-new-ceo/amp/", "date": "2026-04-10", "summary": "Blackstone and TPG have completed their acquisition of Hologic, valuing the company at up to $79 per share, making Hologic a private entity. José (Joe) E. Almeida has been appointed as the new Chief Executive Officer, succeeding Stephen MacMillan. The acquisition aims to further Hologic's mission in women's health with increased investment in innovation.", "sentiment_score": 0.021827, "sentiment_label": "Neutral", "relevance_score": 0.339637, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) president exits stock in $76 cash-and-CVR merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-648eec461ef2.html", "date": "2026-04-10", "summary": "Hologic Inc.'s President, GYN Surgical, Brandon Schnittker, has exited his equity holdings in the company as part of its merger into a wholly owned subsidiary of Hopper Parent Inc. The merger deal converted each Hologic share into $76.00 in cash plus one contingent value right (CVR) for up to an additional $3.00, resulting in Schnittker no longer beneficially owning any Hologic common stock. The filing details the disposition of various equity awards, including common stock, non-qualified stock ", "sentiment_score": 0.100223, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) CFO has equity awards cashed out in Hopper merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-35a0bd20b3ee.html", "date": "2026-04-10", "summary": "Hologic Inc.'s Chief Financial Officer Karleen Oberton had her equity awards, including non-qualified stock options, performance stock units, and common stock, cashed out in connection with Hologic's merger with Hopper Parent Inc. Each share of Hologic common stock was converted into $76.00 in cash plus one contingent value right (CVR) worth up to an additional $3.00. As a result, Oberton no longer beneficially owns any Hologic common stock, with her equity position replaced by the cash and CVR ", "sentiment_score": 0.145482, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) COO exits equity as merger pays $76 plus CVR per share", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-0b8386fcf7c1.html", "date": "2026-04-10", "summary": "Hologic, Inc.'s Chief Operating Officer, Mitchell D. Essex, has disposed of all his equity holdings in the company following its acquisition. Under the merger terms, each Hologic common share was converted into the right to receive $76.00 in cash plus a contingent value right for up to an additional $3.00, resulting in Essex no longer beneficially owning any Hologic common stock. This Form 4 filing details the mechanics of how his stock options, performance stock units, and common shares were tr", "sentiment_score": 0.10368, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) executive equity awards cancelled and cashed out in merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-6ab99e468d3b.html", "date": "2026-04-09", "summary": "Hologic executive Jan Verstreken's equity awards were cancelled and converted into cash and contingent value rights following the company's merger with Hopper Parent Inc. Each Hologic common stock share was converted into $76.00 in cash plus a CVR potentially worth up to $3.00. Verstreken no longer beneficially owns Hologic common stock as a result of this transaction, detailed in a recent Form 4 filing.", "sentiment_score": 0.026574, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) counsel’s shares converted to $76 cash plus CVR in merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-a1d8c07801ed.html", "date": "2026-04-09", "summary": "Hologic, Inc. completed a merger in which each share of common stock was converted into the right to receive $76.00 in cash plus one contingent value right for up to an additional $3.00 in cash per share. As a result, General Counsel Anne M. Liddy disposed of outstanding stock options, performance stock units, restricted stock units, and 28,052 shares of common stock, and no longer beneficially owns any Hologic common stock. This transaction signifies the company's transition to a wholly owned s", "sentiment_score": 0.123818, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) SVP stock converted at $76 plus CVR in merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-0a0053abe209.html", "date": "2026-04-09", "summary": "Diana De Walt, SVP of Human Resources at Hologic (HOLX), disposed of 7,603 shares due to the company's merger with Hopper Parent Inc. Each share was converted into $76.00 in cash plus one contingent value right (CVR) potentially worth up to $3.00. This transaction resulted in De Walt no longer beneficially owning any Hologic common shares.", "sentiment_score": 0.001569, "sentiment_label": "Neutral", "relevance_score": 0.303874, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) director exits equity as merger pays $76 cash plus CVR", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-b4877956c892.html", "date": "2026-04-09", "summary": "Hologic, Inc. director Stacey D. Stewart reported the disposition of 15,049 non-qualified stock options and 8,358 shares of common stock to the company. These transactions were a direct result of a completed merger where each Hologic common share was converted into $76.00 in cash and one contingent value right of up to $3.00. Stewart no longer beneficially owns Hologic common stock, as his equity awards were converted according to the merger agreement.", "sentiment_score": 0.030832, "sentiment_label": "Neutral", "relevance_score": 0.308345, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) director exits position as merger pays $76 plus CVRs", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-7dc0dcc26cc6.html", "date": "2026-04-09", "summary": "Hologic, Inc. director Christiana Stamoulis has disposed of all her equity holdings in the company, including 50,526 shares of common stock and various non-qualified stock options, as part of a merger deal. Under the terms of the merger, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right (CVR) that could pay up to an additional $3.00 per share. This transaction leaves Ms. Stamoulis with no remaining Hologic equity.", "sentiment_score": 0.016686, "sentiment_label": "Neutral", "relevance_score": 0.318244, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) director exits stake as Hopper merger pays cash and CVRs", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-69fa98cd6058.html", "date": "2026-04-09", "summary": "Hologic director Wayde D. McMillan has reported the disposition of his equity in the company following its merger with Hopper Parent Inc. McMillan surrendered his non-qualified stock options and common stock, with his time-vesting restricted stock units also converted as per the merger agreement. He no longer beneficially owns any Hologic common stock, with each share converting into $76.00 in cash and one contingent value right potentially worth an additional $3.00.", "sentiment_score": 0.309334, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (NASDAQ: HOLX) director equity cashed out in merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-c89d3f95c266.html", "date": "2026-04-09", "summary": "Hologic Inc. director Martin D. Madaus has fully divested his equity holdings in the company due to its recent merger. On April 7, 2026, he surrendered all his non-qualified stock options and common shares, both direct and indirect, as part of the merger agreement where Hologic stock was converted to cash and contingent value rights. This resulted in him no longer beneficially owning any Hologic common stock.", "sentiment_score": -0.128831, "sentiment_label": "Neutral", "relevance_score": 0.951687, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Merger leaves Hologic (HOLX) executive without any common shares", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-75e9ade68ac8.html", "date": "2026-04-09", "summary": "Hologic's President of Diagnostic Solutions, Jennifer M. Schneiders, reported the disposition of 41,462 common shares and various non-qualified stock options and performance stock units as a result of the company's merger. Under the October 21, 2025 merger agreement, each Hologic common share was converted into $76.00 in cash plus a contingent value right of up to $3.00, leading to Schneiders no longer beneficially owning any Hologic common stock. All equity awards were cashed out or converted i", "sentiment_score": 0.054344, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.224, "confidence": 0.22 } }, { "source": "alpha_vantage", "title": "Merger cashes out Hologic (HOLX) director Hantson’s stock and options", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-d8cc2c32963e.html", "date": "2026-04-09", "summary": "Hologic director Ludwig Hantson reported the disposition of all his equity awards, including stock options and common shares, in connection with the company's merger. Under the merger agreement, each Hologic common share was converted into $76.00 in cash plus a contingent value right of up to $3.00. This transaction was a mechanical step due to the merger, not an open-market sale, and Hantson no longer beneficially owns any Hologic common stock.", "sentiment_score": 0.049092, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Director leaves Hologic (HOLX) after $76 cash plus CVR merger payout", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-ef341d94e8c6.html", "date": "2026-04-09", "summary": "Hologic director Charles J. Dockendorff has disposed of all his company equity following the company's merger into Hopper Parent Inc. In the merger, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right worth up to $3.00. This transaction leaves Mr. Dockendorff with no direct or indirect beneficial ownership of Hologic common stock, as detailed in a recent Form 4 filing.", "sentiment_score": 0.024887, "sentiment_label": "Neutral", "relevance_score": 0.336783, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic (HOLX) officer reports equity cash-out and loss of shares after merger", "url": "https://www.stocktitan.net/sec-filings/HOLX/form-4-hologic-inc-insider-trading-activity-0a9211f5e7b9.html", "date": "2026-04-09", "summary": "Hologic Inc.'s Principal Accounting Officer, Benjamin Jordan Cohn, reported the cash-out and cancellation of his equity awards following the company's merger. This involved the disposition of non-qualified stock options and 17,964 shares of common stock, as each share was converted into $76.00 in cash plus one contingent value right potentially worth up to an additional $3.00. As a result, Cohn no longer beneficially owns any Hologic common stock.", "sentiment_score": 0.01599, "sentiment_label": "Neutral", "relevance_score": 0.342669, "sentiment": { "label": "negative", "score": -0.226, "confidence": 0.23 } }, { "source": "alpha_vantage", "title": "Casey’s CEO: Being added to S&P 500 ‘reflects the enduring strength of our business’", "url": "https://cspdailynews.com/company-news/caseys-ceo-being-added-sp-500-reflects-enduring-strength-our-business", "date": "2026-04-09", "summary": "Casey's General Stores Inc. has been added to the S&P 500, a significant milestone for the company since becoming publicly traded in 1983. CEO Darren Rebelez stated that this inclusion reflects the enduring strength, strong financial performance, and ratable growth of their business. Casey's, which replaced Hologic Inc. in the index, has shown robust financial performance, including a 49.3% increase in net income for the third quarter and an expected 18% to 20% increase in fiscal 2026 EBITDA.", "sentiment_score": -0.255406, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.869329, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "Casey’s CEO: Being added to S&P 500 ‘reflects the enduring strength of our business’", "url": "https://www.cspdailynews.com/company-news/caseys-ceo-being-added-sp-500-reflects-enduring-strength-our-business", "date": "2026-04-09", "summary": "Casey's General Stores Inc. has been added to the S&P 500, a move its CEO, Darren Rebelez, called a \"significant milestone\" reflecting the business's enduring strength, financial performance, and growth. This marks the first time the convenience-store chain has joined the S&P 500 since going public in 1983. The company, which replaced Hologic Inc., saw strong financial results in its latest quarter, with net income up 49.3%.", "sentiment_score": -0.104934, "sentiment_label": "Neutral", "relevance_score": 0.883504, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "ImpediMed Taps Former Hologic Executive for Top Job", "url": "https://www.mpo-mag.com/breaking-news/impedimed-taps-former-hologic-executive-for-top-job/", "date": "2026-04-09", "summary": "ImpediMed has appointed Erik Anderson, former president of Hologic Inc.'s Breast and Skeletal Health Division, as its new managing director and CEO. Anderson's focus will be on accelerating revenue growth, expanding the adoption of ImpediMed's SOZO platform, particularly in the U.S., and steering the company towards sustainable profitability. This leadership change aims to leverage Anderson's extensive commercial experience in the medical technology sector to capitalize on ImpediMed's growing bu", "sentiment_score": 0.01588, "sentiment_label": "Neutral", "relevance_score": 0.32407, "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Freshpet Stock Climbs 3% as TD Cowen Raises Rating On Strong Sales", "url": "https://www.tikr.com/blog/freshpet-stock-climbs-3-as-td-cowen-raises-rating-on-strong-sales", "date": "2026-04-09", "summary": "Freshpet (FRPT) stock rose 3% after TD Cowen upgraded the company to Buy, setting an $80 price target, driven by strong fiscal 2025 results where the company surpassed $1 billion in annual revenue and achieved positive free cash flow a year early. Despite a challenging pet food market, Freshpet outgrew the category, maintained market share, and expanded margins, leading analysts to believe the worst is over and the company's growth trajectory is back on track. The upgrade highlights Freshpet's i", "sentiment_score": 0.224604, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.644428, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "Ultra Clean Stock: What the Q4 Earnings Call Revealed About the Next Two Years", "url": "https://www.tikr.com/blog/ultra-clean-stock-what-the-q4-earnings-call-revealed-about-the-next-two-years", "date": "2026-04-09", "summary": "Ultra Clean Holdings (UCTT) is positioning itself for significant growth fueled by AI infrastructure expansion, with its stock up 282% from its 52-week low. The company's \"UCT 3.0\" strategy targets a $4 billion annual revenue run rate by capitalizing on AI, advanced memory, and gate-all-around logic transitions. Analysts are unanimously bullish, with a mean price target of $81.25, suggesting substantial upside as the company's financial performance is expected to recover strongly in 2026 and bey", "sentiment_score": 0.016071, "sentiment_label": "Neutral", "relevance_score": 0.5437, "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Casey's General Stores, Inc.(NasdaqGS: CASY) added to S&P 500 Equal Weighted", "url": "https://www.marketscreener.com/news/casey-s-general-stores-inc-nasdaqgs-casy-added-to-s-p-500-equal-weighted-ce7e50dbde8cf526", "date": "2026-04-09", "summary": "Casey's General Stores, Inc. (NasdaqGS: CASY) has been added to the S&P 500 Equal Weighted Index, among several other S&P indices. This move signifies increased visibility for the convenience store and pizza chain, which operates approximately 2,900 stores across 17 states. The addition to the S&P 500 follows an earlier announcement that Casey's would replace Hologic Inc. in the S&P 500 prior to market open on April 9.", "sentiment_score": -0.127873, "sentiment_label": "Neutral", "relevance_score": 0.628327, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic Goes Private In $18 Billion Blackstone, TPG Acquisition", "url": "https://www.sahmcapital.com/news/content/hologic-goes-private-in-18-billion-blackstone-tpg-acquisition-2026-04-08", "date": "2026-04-09", "summary": "Hologic Inc. has completed its $18.3 billion acquisition by funds managed by Blackstone Inc. and TPG Inc. Hologic's stock has ceased trading and will be delisted from Nasdaq. Shareholders will receive $76 per share in cash and a non-tradable contingent value right of up to $3 per share, tied to revenue milestones.", "sentiment_score": 0.439858, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "HOLX Financials: Revenue Breakdown, Margins & Competitor Comparison", "url": "https://intellectia.ai/en/stock/HOLX/financials", "date": "2026-04-09", "summary": "The article provides a financial overview of Hologic Inc (HOLX), detailing its revenue breakdown, profitability margins, and competitive positioning. Disposables are identified as the largest revenue contributor at 64.3%, while the company maintains strong gross, operating, and net margins. A comparison with competitors ZBH and WST highlights HOLX's efficient financial performance within the Advanced Medical Equipment & Technology industry.", "sentiment_score": 0.435749, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic, Inc.(NasdaqGS:HOLX) dropped from S&P 500 Health Care Equipment & Services (Industry Group)", "url": "https://www.marketscreener.com/news/hologic-inc-nasdaqgs-holx-dropped-from-s-p-500-health-care-equipment-services-industry-group-ce7e50dbdd89f420", "date": "2026-04-09", "summary": "Hologic, Inc. (NasdaqGS:HOLX) has been removed from the S&P 500 Health Care Equipment & Services Industry Group, as well as multiple other S&P indices including the S&P 500, S&P Global 1200, and S&P Healthcare Equipment Select Industry Index. This news was published on April 8, 2026, at 08:28 pm EDT. Hologic specializes in diagnostic products and medical imaging systems primarily for women's health.", "sentiment_score": -0.434442, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "Hologic, Inc.(NasdaqGS: HOLX) dropped from S&P 500 Equal Weighted", "url": "https://www.marketscreener.com/news/hologic-inc-nasdaqgs-holx-dropped-from-s-p-500-equal-weighted-ce7e50dbdd89f522", "date": "2026-04-08", "summary": "Hologic, Inc. (NasdaqGS: HOLX) has been removed from the S&P 500 Equal Weighted index, following its delisting from several other S&P and FTSE indices on April 8th and 9th, 2026. The company specializes in women's health products, including diagnostic tools, medical imaging, and surgical systems. This removal follows a series of similar actions across various major indices, indicating a possible re-evaluation of its market position or index criteria.", "sentiment_score": -0.257227, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Hologic, Inc.(NasdaqGS: HOLX) dropped from S&P Composite 1500", "url": "https://www.marketscreener.com/news/hologic-inc-nasdaqgs-holx-dropped-from-s-p-composite-1500-ce7e50dbdd89f425", "date": "2026-04-08", "summary": "Hologic, Inc. (NasdaqGS:HOLX) was removed from the S&P Composite 1500 index. This delisting marks one of several index removals for the company on April 8th, including the S&P 500 and FTSE All-World Index CI. Hologic specializes in diagnostic products, medical imaging, and surgical products focused on women's health.", "sentiment_score": 0.004212, "sentiment_label": "Neutral", "relevance_score": 0.331403, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "42000404", "title": "Impact of less invasive axillary staging procedures after neoadjuvant systemic therapy on adjuvant systemic therapy indications in HER2-positive and triple-negative breast cancer.", "authors": "Claassens EL et al.", "journal": "European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/42000404/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "42000378", "title": "Cost and efficiency of universal versus selective next generation sequencing for advanced stage endometrial cancer.", "authors": "Bashi A et al.", "journal": "Gynecologic oncology", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/42000378/", "sentiment": { "label": "negative", "score": -0.226, "confidence": 0.23 } }, { "source": "pubmed", "pmid": "41998406", "title": "Viral variant but not host factors associate with SARS-CoV-2 viral kinetics.", "authors": "Hahn WO et al.", "journal": "Communications medicine", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41998406/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41990403", "title": "Development and genomic characterization of a diverse HIV-1 variant reference panel for nucleic acid-based testing.", "authors": "Zhao J et al.", "journal": "Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41990403/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41986464", "title": "Conversion of DXA body composition measurements across different devices: A standardized approach.", "authors": "Siekman B et al.", "journal": "European journal of clinical nutrition", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41986464/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41982097", "title": "Leveraging the Potential of Ultra-High Resolution Photon Counting Detector CT Angiography of the Cerebral Vasculature by Using Low kVp and Sharp Kernels.", "authors": "Pinckaers FME et al.", "journal": "Investigative radiology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41982097/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41981246", "title": "Interpretable multiple instance learning for hematologic diagnosis from peripheral blood smears.", "authors": "Singi S et al.", "journal": "Communications medicine", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41981246/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41976279", "title": "Informative High-Risk HPV Genotyping in Cervical Cancer Screening: Integrated Analysis of Cytology and p16/Ki67 Dual Staining.", "authors": "Trzeszcz M et al.", "journal": "Cancers", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41976279/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41966613", "title": "Evaluation of the clinical and analytical performance of the LIAISON PLEX for the qualitative detection of human adenovirus in respiratory samples.", "authors": "Norton J et al.", "journal": "Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology", "date": "2026 Apr 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41966613/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41966529", "title": "Comparison of the AccuPower HIV-1 Quant Kit and Aptima HIV-1 Quant Dx Assay for quantification of HIV-1 plasma viral load.", "authors": "Kim TY et al.", "journal": "Diagnostic microbiology and infectious disease", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41966529/", "sentiment": { "label": "negative", "score": -0.612, "confidence": 0.61 } }, { "source": "pubmed", "pmid": "41965791", "title": "PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.", "authors": "Hörner M et al.", "journal": "NPJ breast cancer", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41965791/", "sentiment": { "label": "negative", "score": -0.128, "confidence": 0.13 } }, { "source": "pubmed", "pmid": "41961087", "title": "Adjusting fracture probability according to duration of diabetes: the Manitoba BMD Registry.", "authors": "Leslie WD et al.", "journal": "Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41961087/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41957676", "title": "Long-read sequencing identifies aberrant fragmentation patterns linked to elevated cell-free DNA levels in cancer.", "authors": "Berman BP et al.", "journal": "Genome biology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41957676/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41953225", "title": "Fetoscopic repair of myeloschisis: optimizing the three-layer closure.", "authors": "Weber MD et al.", "journal": "Neurosurgical focus: Video", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41953225/", "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "pubmed", "pmid": "41950750", "title": "A peer-delivered mobile model to enhance access to hepatitis C point-of-care testing and treatment: The Peers on Wheels study.", "authors": "Stowe MJ et al.", "journal": "The International journal on drug policy", "date": "2026 Apr 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41950750/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41950749", "title": "Peer- and nurse-led outreach, financial incentives, and point-of-care testing to enhance testing and treatment for hepatitis C among people who have used drugs or experienced homelessness: The REACH_U Study.", "authors": "Marinho I et al.", "journal": "The International journal on drug policy", "date": "2026 Apr 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41950749/", "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41937539", "title": "It Is All About Energy-the Changing Role of X-ray Photons in Photon-counting Detector Computed Tomography: What the Radiologist Needs to Know About kV and keV.", "authors": "Hoeijmakers EJI et al.", "journal": "Investigative radiology", "date": "2026 Apr 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41937539/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41936820", "title": "Validation of a Low-Volume (100 μL) Plasma Protocol for HIV-1 RNA Quantification Using the Hologic Aptima HIV-1 Quant Dx Assay.", "authors": "Madurai LS et al.", "journal": "The Journal of molecular diagnostics : JMD", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41936820/", "sentiment": { "label": "negative", "score": -0.612, "confidence": 0.61 } }, { "source": "pubmed", "pmid": "41931983", "title": "Can large language models like ChatGPT and Gemini interpret cervical cytology accurately?", "authors": "Geetha SD", "journal": "Annals of diagnostic pathology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41931983/", "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "pubmed", "pmid": "41930568", "title": "Prediction of spontaneous onset of labor at term using clinical, ultrasound, and biochemical data: A multicenter prospective observational study (the PREDICT study).", "authors": "Migliorelli F et al.", "journal": "Acta obstetricia et gynecologica Scandinavica", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41930568/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41927463", "title": "Point-of-care testing for chlamydia and gonorrhoea: a narrative review of patient perspectives and implementation into non-traditional settings.", "authors": "Griner SB et al.", "journal": "Sexually transmitted infections", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41927463/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41926089", "title": "Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.", "authors": "Park CS et al.", "journal": "JAMA oncology", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41926089/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41925922", "title": "Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.", "authors": "Hörner M et al.", "journal": "Breast cancer research and treatment", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41925922/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41925307", "title": "Development and evaluation of dried urine strip for genital chlamydia and gonorrhea testing.", "authors": "Gibbons S et al.", "journal": "Journal of clinical microbiology", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41925307/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41920021", "title": "Longitudinal Deterioration in Nutritional Status Associated With Increased Risk of Sarcopenia in Community-Dwelling Aged Adults: A Prospective Cohort Study.", "authors": "Lim HJ et al.", "journal": "Journal of cachexia, sarcopenia and muscle", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41920021/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41918854", "title": "Treatment Approaches for Refractory Mycoplasma genitalium Infection.", "authors": "Tenney R et al.", "journal": "Open forum infectious diseases", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41918854/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41915825", "title": "The Vaginal Microbiota in Pig-Tailed Macaques and Colonization with Neisseria gonorrhoeae.", "authors": "Srinivasan S et al.", "journal": "Sexually transmitted diseases", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41915825/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41914308", "title": "Cervical Cancer Elimination in Australia and the Asia Pacific: Progress and Barriers.", "authors": "Yuill S et al.", "journal": "The Medical journal of Australia", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41914308/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41913316", "title": "Psychosocial Burden of Women With Cervical Intraepithelial Neoplasia in Japan: Results of A Web-Based Survey.", "authors": "Sato K et al.", "journal": "The journal of obstetrics and gynaecology research", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41913316/", "sentiment": { "label": "negative", "score": -0.44, "confidence": 0.44 } }, { "source": "pubmed", "pmid": "41885612", "title": "Comparison of Respiratory Syncytial Virus (RSV)-Specific Antibody Durability in Pregnant/Postpartum Individuals and Older Adults After RSV Vaccination.", "authors": "Kachikis A et al.", "journal": "The Journal of infectious diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41885612/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41885439", "title": "Positive nucleic acid amplification test results are rarely indicative of a viable rectal Chlamydia trachomatis infection among men with anal exposures other than receptive anal sex.", "authors": "Khosropour CM et al.", "journal": "Sexually transmitted diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41885439/", "sentiment": { "label": "positive", "score": 0.557, "confidence": 0.56 } }, { "source": "pubmed", "pmid": "41874876", "title": "Recent Trends in Whole-Breast Irradiation Versus Partial-Breast Irradiation in Ductal Carcinoma in situ with Breast-Conserving Surgery 2011-2021: A National Cancer Database Study.", "authors": "Jeng A et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874876/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874107", "title": "Estimating the sensitivity of non-treponemal and treponemal antibody tests in primary syphilis.", "authors": "Sweitzer SF et al.", "journal": "Sexually transmitted diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874107/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41852862", "title": "Management and Outcomes of Complications Related to BioZorb Use in Breast-Conserving Surgery: A Retrospective Single-Center Case Series Analysis.", "authors": "Baz C et al.", "journal": "Ochsner journal", "date": "2026 Sprin", "url": "https://pubmed.ncbi.nlm.nih.gov/41852862/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41806477", "title": "A 3D-printed anthropomorphic breast phantom with realistic anatomy and attenuation properties for spatially resolved dosimetry in mammography.", "authors": "Liu Y et al.", "journal": "Physics in medicine and biology", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41806477/", "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "pubmed", "pmid": "41801760", "title": "Vaccine-Elicited Antibody Responses to Influenza A(H3N2) Subclade K.", "authors": "Wang L et al.", "journal": "JAMA", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41801760/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41747748", "title": "Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials.", "authors": "Ndung'u T et al.", "journal": "The lancet. HIV", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41747748/", "sentiment": { "label": "negative", "score": -0.361, "confidence": 0.36 } }, { "source": "pubmed", "pmid": "41719678", "title": "Real-world treatment patterns and sequencing in patients with advanced / metastatic HR+/HER2- breast cancer in Europe and the United States.", "authors": "Mahtani R et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41719678/", "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41707479", "title": "Late distant recurrence prediction model in premenopausal women with ER-positive/HER 2-negative breast cancer: A multicenter retrospective study.", "authors": "Shin DS et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41707479/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41689946", "title": "Clinicopathologic characteristics and lymph node status in the NAUTILUS clinical trial:KBCSG-21.", "authors": "Ryu JM et al.", "journal": "European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41689946/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41679383", "title": "Agreement and systematic difference between bioelectrical impedance analysis and dual-energy X-ray absorptiometry for appendicular lean mass in 1617 community-dwelling older adults: The Bunkyo Health Study.", "authors": "Nakagata T et al.", "journal": "Clinical nutrition ESPEN", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41679383/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41678855", "title": "Visceral adipose tissue in obesity: A comparison between DXA and MRI measures.", "authors": "de Paula E Mancilha T et al.", "journal": "Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry", "date": "2026 Apr-J", "url": "https://pubmed.ncbi.nlm.nih.gov/41678855/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41651703", "title": "The global epidemiology of injecting drug use, HIV, viral hepatitis and tuberculosis among people who are incarcerated: a multistage systematic review.", "authors": "Degenhardt L et al.", "journal": "The International journal on drug policy", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41651703/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41651702", "title": "Global coverage of interventions for reduction of injecting drug use-related harm, HIV, viral hepatitis and tuberculosis in prisons and other carceral settings: A systematic review.", "authors": "Santo T Jr et al.", "journal": "The International journal on drug policy", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41651702/", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } }, { "source": "pubmed", "pmid": "41637791", "title": "Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.", "authors": "O'Regan RM et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41637791/", "sentiment": { "label": "negative", "score": -0.898, "confidence": 0.9 } }, { "source": "pubmed", "pmid": "41530029", "title": "Impact of Breast Density on Screening Performance Metrics: An Analysis of 301,400 Screening Digital Breast Tomosynthesis (DBT) Examinations.", "authors": "Kniss AS et al.", "journal": "Academic radiology", "date": "2026-04-21", "url": "https://pubmed.ncbi.nlm.nih.gov/41530029/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41489384", "title": "Evaluation of Alinity m STI Assay for Simultaneous Detection of Chlamydia trachomatis , Neisseria gonorrhoeae , Trichomonas vaginalis , and Mycoplasma genitalium in Female Urogenital Specimens.", "authors": "Gentil LG et al.", "journal": "Sexually transmitted diseases", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41489384/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41427726", "title": "Evaluation of Alinity m Sexually Transmitted Infection Assay for Simultaneous Detection of Chlamydia trachomatis , Neisseria gonorrhoeae , Trichomonas vaginalis , and Mycoplasma genitalium in Male Urine Specimens.", "authors": "Cullum R et al.", "journal": "Sexually transmitted diseases", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41427726/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41401234", "title": "Diagnostic accuracy and prognostic value of CMR in patients with suspected acute coronary syndrome: a meta-analysis.", "authors": "van Cauteren YJM et al.", "journal": "European heart journal. Cardiovascular Imaging", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41401234/", "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "pubmed", "pmid": "41400247", "title": "Challenges in the future of cancer screening.", "authors": "Lynge E et al.", "journal": "International journal of cancer", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41400247/", "sentiment": { "label": "negative", "score": -0.625, "confidence": 0.62 } } ] } }